Targets › TREML1
1 program from 1 company in 1 trial: 1 Phase 2; Hematology; next expected readout Nov 2027.
Cell surface receptor that may play a role in the innate and adaptive immune response. (UniProt, Q86YW5)
Open in Phaseline: the race on TREML1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hemab ApS | Sutacimig Bispecific antibody binding activated factor VII and TLT-1 on platelets | F7, TREML1 | Phase 2 | Congenital Factor VII Deficiency | Nov 2027 |
Congenital Factor VII Deficiency (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.